Press Releases

    • JUL 10 2017

    Mechanistic Study Uncovers New Utility of ONC201 Mechanism in Lymphoma

    Philadelphia, PA (July 10, 2017) – Oncoceutics, Inc. announced the publication of a scientific manuscript from collaborators at the University of Texas MD Anderson Cancer Center (MDACC) that describes ONC201’s ability to control a set of anti-cancer signaling pathways to induce cell death in tumor, but not  normal cells. The publication, from the laboratory of

    • JUN 28 2017

    Oncoceutics Extends Patent Family to Include ONC201 in Leukemias

    Philadelphia, PA (June 28, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #9,688,679 for the use of ONC201 to treat all leukemias, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical

    • MAY 30 2017

    Efficacy Results for ONC201 in Recurrent Glioblastoma Published

    Philadelphia, PA (May 30, 2017) – Oncoceutics, Inc. announced that results from the first cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Oncotarget. The study, conducted at Massachusetts General Hospital (MGH) and the Dana Farber Cancer Institute (DFCI), demonstrated

    • MAY 22 2017

    Cell Cycle Article Describes Anti-Cancer Efficacy of Imipridones

    Philadelphia, PA (May 18, 2017) – Oncoceutics, Inc. announced that the journal Cell Cycle recently published a manuscript detailing the anti-cancer efficacy of members of the imipridone family. The publication, from the laboratory of Wafik El-Deiry MD, PhD, FACP, Scientific Founder of Oncoceutics, and Deputy Cancer Center Director for Translational Research of the Fox Chase